Incidence and risk of developing photosensitivity with targeted anticancer therapies

J Am Acad Dermatol. 2019 Oct;81(4):1009-1011. doi: 10.1016/j.jaad.2019.01.077. Epub 2019 Feb 5.
No abstract available

Publication types

  • Letter
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects
  • Clinical Trials as Topic
  • Humans
  • Incidence
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*
  • Nivolumab / adverse effects
  • Photosensitivity Disorders / epidemiology*
  • Piperidines / adverse effects
  • Quinazolines / adverse effects
  • Risk Assessment
  • Vemurafenib / adverse effects

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • Piperidines
  • Quinazolines
  • Vemurafenib
  • Nivolumab
  • vandetanib